PMCB - PharmaCyte Biotech, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0816
-0.0024 (-2.86%)
As of 10:50AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.0840
Open0.0845
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0805 - 0.0885
52 Week Range0.0300 - 0.1100
Volume474,543
Avg. Volume2,917,319
Market Cap82.682M
Beta2.97
PE Ratio (TTM)N/A
EPS (TTM)-0.0160
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire4 days ago

    PharmaCyte Biotech Successfully Completes Another FDA Required Study Necessary for Submitting Investigational New Drug Application

    PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully completed the comprehensive characterization of its proprietary cell clone known as 22P1G. The 22P1G cells constitute the cells in the Master Cell Bank (MCB) that were prepared and tested by PharmaCyte’s contractor, Eurofins Lancaster Laboratories. The cells from the MCB will serve as the active pharmaceutical ingredient (API) in the company’s Cell-in-a Box® capsules that will be used (together with low doses of the cancer prodrug ifosfamide) for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC) in its planned clinical trial.

  • GlobeNewswire12 days ago

    PharmaCyte’s Clinical Trial in Pancreatic Cancer Serves as Proving Ground for Its One of a Kind Cell Encapsulation Technology

    PharmaCyte Biotech, Inc. (PMCB) is closing in on what will be a landmark event in this small company’s history—a clinical trial in the United States under the watchful eye of the most powerful drug regulatory agency in the world, the U.S. Food and Drug Administration (FDA).  It would be the company’s first clinical trial ever and could serve as the event that changes the way solid cancerous tumors are treated, while at the same time, proving that PharmaCyte has what is considered the “Holy Grail” for diabetes—an encapsulation technology that can live inside the human body and protect the cells inside from the body’s own immune response. PharmaCyte’s signature live-cell encapsulation technology, Cell-in-a-Box®, is a one-of-a-kind cell encapsulation technology, and its planned clinical trial for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer or LAPC, could very well attract a lot of attention from companies, organizations and investors in both the cancer and diabetes spaces.

  • Business Wire17 days ago

    PharmaCyte Biotech Receives Certificates of Analysis from Eurofins on Cells Used for Pancreatic Cancer Therapy

    PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has received Certificates of Analysis and final reports of all tests that were performed by its contractor Eurofins on cells from PharmaCyte’s Master Cell Bank (MCB). The cells that underwent testing will be encapsulated and then used in PharmaCyte’s planned clinical trial in patients with locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC).

  • Business Wire19 days ago

    PharmaCyte Biotech CEO and CSO Interviewed About IND, Planned Clinical Trial in Pancreatic Cancer, CRO and More

    PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the release of a recorded interview with the company’s Chief Executive Officer, Kenneth L. Waggoner, and its Chief Scientific Officer, Prof. Walter H. Günzburg.

  • GlobeNewswire28 days ago

    PharmaCyte Closing in on Submission of Crucial Investigational New Drug Application to Begin Clinical Trial in Pancreatic Cancer

    The key to submitting the IND is and always has been satisfying regulatory requirements.  In short, PharmaCyte must generate the necessary data that the FDA requires for any treatment—but especially a treatment that is deemed a “biologic” by the FDA and comprised of living cells that would be placed inside a human’s body. PharmaCyte just announced that it has completed and passed 29 different tests from its Master Cell Bank (MCB), which is made up of cells that will be used in its planned clinical trial in patients with LAPC.  The successful completion of these tests is the final hurdle before encapsulation and testing of the encapsulated cells can begin at Austrianova.

  • Business Wirelast month

    PharmaCyte Biotech Successfully Completes 29 Tests Conducted on Live Cells Used in Pancreatic Cancer Therapy

    PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the cells it will encapsulate and then use in its planned clinical trial in patients with locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC) have successfully passed all 29 tests required by the U.S. Food and Drug Administration (FDA). Most of the tests were conducted by PharmaCyte’s contractor, Eurofins Lancaster Laboratories, Inc. (Eurofins). The rest of the tests were conducted by third party laboratories subcontracted by Eurofins.

  • Business Wirelast month

    PharmaCyte Biotech Successfully Completes Pore Size Studies in Cell-in-a-Box® Capsules Used in Pancreatic Cancer Therapy

    PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully completed the “pore size studies” on its Cell-in-a Box® capsules that are required by the U.S. Food and Drug Administration (FDA). PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, explained the significance of the study saying, “PharmaCyte’s treatment for locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC) utilizes genetically engineered live human cells that produce a particularly potent cytochrome P450 enzyme that is able to activate the chemotherapy prodrug ifosfamide.

  • Business Wire2 months ago

    PharmaCyte Biotech Reports Successful Completion of Long-term Studies on Cells Used in Pancreatic Cancer Therapy

    PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the successful results of long-term studies on the type of cells that will be encapsulated using its Cell-in-a-Box® technology and then combined with low doses of the cancer prodrug ifosfamide for the treatment of patients with locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC).

  • Business Wire2 months ago

    PharmaCyte Biotech Successfully Completes Multiple Course Ifosfamide Study

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully completed a “multiple course ifosfamide study” required by the U.S.

  • Business Wire2 months ago

    PharmaCyte’s Clinical Trial Cells Arrive Safely at Austrianova’s Encapsulation Facility

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the vials of cells from PharmaCyte’s Master Cell Bank that were shipped by Eurofins Lancaster Laboratories to Austrianova’s encapsulation facility in Thailand have arrived ...

  • Business Wire3 months ago

    PharmaCyte Ships Clinical Trial Cells to Austrianova for Encapsulation

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced that vials of cells from PharmaCyte’s Master Cell Bank have been shipped by Eurofins Lancaster Laboratories to Austrianova’s encapsulation facility in Thailand.

  • Business Wire3 months ago

    PharmaCyte Biotech Files Patent Applications to Broaden Protection of Cancer Therapy in U.S. and Worldwide

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has filed a U.S.

  • Business Wire4 months ago

    PharmaCyte Discusses Phase 2b Clinical Trial in Pancreatic Cancer

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today explains PharmaCyte’s plans to conduct a Phase 2b clinical trial.

  • Business Wire4 months ago

    PharmaCyte Announces Successful Completion of 6-Month Stability Study on Encapsulated Cells for Clinical Trial

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its 6-month study on storage of the frozen encapsulated cells necessary for the determination of an “initial shelf life” has been successfully completed by Austrianova....

  • Business Wire4 months ago

    PharmaCyte Announces Completion of Preparatory Work and Commencement of Testing by Eurofins of Cells from Its Master Cell Bank

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the steps necessary for the testing of cells from its Master Cell Bank have been completed by Eurofins Lancaster Laboratories and that testing began last month.

  • Business Wire5 months ago

    PharmaCyte Announces Completion of Master Cell Bank

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the Master Cell Bank of cells that will be used in its upcoming trial in patients with locally advanced non-metastatic and inoperable pancreatic cancer has been fully populated....

  • Business Wire6 months ago

    PharmaCyte Biotech Meets with Oncology Advisory Board

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it recently met with its Oncology Advisory Board, which was formed to assist in optimizing and finalizing the clinical protocol and other clinical trial-related matters ...

  • Business Wire6 months ago

    PharmaCyte Biotech Announces Production of Master Cell Bank

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today reported that the production of the cells necessary to prepare the Master Cell Bank has started.

  • Business Wire7 months ago

    PharmaCyte Biotech Announces Successful Completion of Cell Testing for Production of Master Cell Bank

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today reported that Eurofins Lancaster Laboratories, a leading Contract Manufacturing Organization that PharmaCyte selected to prepare its Master Cell Bank , has successfully completed its ...

  • Business Wire7 months ago

    British Columbia Securities Commission Revokes Cease Trade Order on PharmaCyte Biotech Securities

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it is providing a summary overview, corporate history and status report to address a regulatory compliance request from the British Columbia Securities Commission which, ...

  • Business Wire8 months ago

    PharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Dr.